Assembly Biosciences Inc.
| NASDAQ: ASMB | Healthcare / Biotechnology / USA |
| 4.28 | -0.0500 | -1.15% | Vol 518.17K | 1Y Perf -74.46% |
| Apr 16th, 2021 16:00 DELAYED |
| BID | 4.28 | ASK | 4.30 | ||
| Open | 4.37 | Previous Close | 4.33 | ||
| Pre-Market | - | After-Market | 4.28 | ||
| - - | - -% |
| Target Price | 11.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 157.01 | Finscreener Ranking | ★★★★★ 62.16 | |
| Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | ★★★★+ 60.20 | |
| Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | ★★★★ 61.74 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
| Market Cap | 171.45M | Earnings Rating | Sell | |
| Price Range Ratio 52W % | 0.72 | Earnings Date | 6th May 2021 |
Today's Price Range 4.224.38 | 52W Range 4.1127.84 | 5 Year PE Ratio Range -7.70-6.40 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -1.83% | ||
| 1 Month | -15.25% | ||
| 3 Months | -30.18% | ||
| 6 Months | -72.60% | ||
| 1 Year | -74.46% | ||
| 3 Years | -91.00% | ||
| 5 Years | -17.53% | ||
| 10 Years | -94.10% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -39.27 | |||
ROE last 12 Months | -23.10 | |||
ROA (5Y Avg) | -22.03 | |||
ROA last 12 Months | -19.03 | |||
ROC (5Y Avg) | -42.75 | |||
ROC last 12 Months | -23.52 | |||
Return on invested Capital Q | -14.90 | |||
Return on invested Capital Y | -24.16 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 30.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.50 | ||||
| 0.73 | ||||
| 2.27 | ||||
| 414.90 | ||||
| -4.40 | ||||
| -1.78 | ||||
| 0.88 | ||||
| 6.01 | ||||
| -30 825 000.00 | ||||
| Forward PE | -1.47 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 8.90 | ||||
| 9.20 | ||||
| 0.03 | ||||
| 0.04 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -65.00 | ||||
| -64.40 | ||||
| - | ||||
| -43.73 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 75.02M | ||||
| 1.87 | ||||
| 77.86 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.90 | -1.11 | -23.33 |
| Q03 2020 | -0.78 | -0.09 | 88.46 |
| Q02 2020 | -0.03 | 0.19 | 733.33 |
| Q01 2020 | -0.98 | -0.76 | 22.45 |
| Q04 2019 | -1.01 | -0.99 | 1.98 |
| Q03 2019 | -0.93 | -0.96 | -3.23 |
| Q02 2019 | -1.10 | -0.72 | 34.55 |
| Q01 2019 | -1.07 | -1.05 | 1.87 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.79 | -3.95 | Negative |
| 6/2021 QR | -0.77 | 12.50 | Positive |
| 12/2021 FY | -3.20 | 8.83 | Positive |
| 12/2022 FY | -2.96 | -10.45 | Negative |
| Next Report Date | 6th May 2021 |
| Estimated EPS Next Report | -0.79 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 518.17K |
| Shares Outstanding | 40.06M |
| Trades Count | 4.32K |
| Dollar Volume | 11.91M |
| Avg. Volume | 1.23M |
| Avg. Weekly Volume | 681.77K |
| Avg. Monthly Volume | 857.90K |
| Avg. Quarterly Volume | 1.33M |
Assembly Biosciences Inc. (NASDAQ: ASMB) stock closed at 4.28 per share at the end of the most recent trading day (a -1.15% change compared to the prior day closing price) with a volume of 519.28K shares and market capitalization of 171.45M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 120 people. Assembly Biosciences Inc. CEO is John G. McHutchison.
The one-year performance of Assembly Biosciences Inc. stock is -74.46%, while year-to-date (YTD) performance is -29.26%. ASMB stock has a five-year performance of -17.53%. Its 52-week range is between 4.11 and 27.84, which gives ASMB stock a 52-week price range ratio of 0.72%
Assembly Biosciences Inc. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 0.73, a price-to-sale (PS) ratio of 2.27, a price to cashflow ratio of 414.90, a PEG ratio of 2.32, a ROA of -19.03%, a ROC of -23.52% and a ROE of -23.10%. The company’s profit margin is -43.73%, its EBITDA margin is -64.40%, and its revenue ttm is $75.02 Million , which makes it $1.87 revenue per share.
Of the last four earnings reports from Assembly Biosciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.79 for the next earnings report. Assembly Biosciences Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Assembly Biosciences Inc. is Strong Buy (1), with a target price of $11, which is +157.01% compared to the current price. The earnings rating for Assembly Biosciences Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Assembly Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Assembly Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.91, ATR14 : 0.30, CCI20 : -92.27, Chaikin Money Flow : -0.26, MACD : -0.44, Money Flow Index : 35.04, ROC : -4.89, RSI : 38.62, STOCH (14,3) : 31.58, STOCH RSI : 0.74, UO : 52.43, Williams %R : -68.42), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Assembly Biosciences Inc. in the last 12-months were: Jacqueline S. Papkoff (Sold 1 297 shares of value $7 983 ), John G. McHutchison (Sold 12 151 shares of value $264 917 ), Luisa M. Stamm (Sold 4 397 shares of value $22 404 )
Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
CEO: John G. McHutchison
Telephone: +1 833 509-4583
Address: 331 Oyster Point Blvd, South San Francisco 94080, CA, US
Number of employees: 120
